| Entry |
|
|---|
| Name |
Esketamine hydrochloride (JAN/USAN);
Spravato (TN) |
|---|
| Product |
|
|---|
| Formula |
C13H16ClNO. HCl
|
|---|
| Exact mass |
273.0687
|
|---|
| Mol weight |
274.1862
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Product (DG01829): | D10627<US> |
|
|---|
| Efficacy |
Antidepressant, NMDA receptor antagonist |
|---|
| Comment |
Treatment of depression
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N01 ANESTHETICS
N01A ANESTHETICS, GENERAL
N01AX Other general anesthetics
N01AX14 Esketamine
D10627 Esketamine hydrochloride (JAN/USAN) <US>
N06 PSYCHOANALEPTICS
N06A ANTIDEPRESSANTS
N06AX Other antidepressants
N06AX27 Esketamine
D10627 Esketamine hydrochloride (JAN/USAN) <US>
USP drug classification [BR:br08302]
Antidepressants
Antidepressants, Other
Esketamine
D10627 Esketamine hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01498 NMDA receptor antagonist
DG01829 Esketamine
D10627 Esketamine hydrochloride
Metabolizing enzyme substrate
DG02919 CYP2B6 substrate
DG01829 Esketamine
D10627 Esketamine hydrochloride
DG01642 CYP2C9 substrate
DG01829 Esketamine
D10627 Esketamine hydrochloride
DG01639 CYP2C19 substrate
DG01829 Esketamine
D10627 Esketamine hydrochloride
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01829 Esketamine
D10627 Esketamine hydrochloride
DG02924 UGT substrate
DG01829 Esketamine
D10627 Esketamine hydrochloride
Target-based classification of drugs [BR:br08310]
Ion channels
Ligand-gated ion channels
Glutamate (ionotropic), NMDA
GRIN (NMDAR)
D10627 Esketamine hydrochloride (JAN/USAN) <US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10627
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10627
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01498 NMDA receptor antagonist
DG01829 Esketamine
Metabolizing enzyme substrate
DG02919 CYP2B6 substrate
DG01829 Esketamine
DG01642 CYP2C9 substrate
DG01829 Esketamine
DG01639 CYP2C19 substrate
DG01829 Esketamine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01829 Esketamine
DG02924 UGT substrate
DG01829 Esketamine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 17
1 C1z C 18.4150 -16.0505
2 C8y C 17.2286 -16.7484
3 C5x C 19.8108 -16.0505
4 C1x C 17.7171 -14.8640
5 N1b N 19.1129 -17.2369
6 C8y C 15.9723 -16.0505
7 C8x C 17.2286 -18.1442
8 C1x C 20.5088 -14.7942
9 O5x O 20.5088 -17.2369
10 C1x C 18.4150 -13.6078
11 C1a C 18.4150 -18.4932
12 C8x C 14.7859 -16.7484
13 X Cl 15.9723 -14.6547
14 C8x C 15.9723 -18.8421
15 C1x C 19.8108 -13.6078
16 C8x C 14.7859 -18.1442
17 X Cl 22.5337 -16.6801
BOND 17
1 1 2 1
2 1 3 1
3 1 4 1
4 1 5 1 #Down
5 2 6 2
6 2 7 1
7 3 8 1
8 3 9 2
9 4 10 1
10 5 11 1
11 6 12 1
12 6 13 1
13 7 14 2
14 8 15 1
15 12 16 2
16 10 15 1
17 14 16 1
|
|---|
